Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20134993 | 1.00 | HTR1D (0.41) | HTR1DHTR1BMAPK7ADAMTS5GRM4 | |
| SCHEMBL20809261 | 0.85 | HTR1D (0.41) | HTR1DHTR1BMAPK7GRM4CYP1A2 | |
| SCHEMBL20135346 | 0.85 | RBP4 (0.42) | MAPK7ADAMTS5HSD11B1HTR2B | |
| SCHEMBL29688380 | 0.85 | RBP4 (0.42) | MAPK7ADAMTS5HSD11B1HTR2B | |
| SCHEMBL20135350 | 0.85 | RBP4 (0.42) | MAPK7ADAMTS5HSD11B1HTR2B | |
| SCHEMBL20135534 | 0.84 | MAPK7 (0.39) | MAPK7ADAMTS5HSD11B1HTR2B | |
| SCHEMBL20135007 | 0.84 | JAK1 (0.48) | — | |
| SCHEMBL20135539 | 0.84 | MAPK7 (0.39) | MAPK7ADAMTS5HSD11B1HTR2B | |
| SCHEMBL20135010 | 0.84 | JAK1 (0.48) | — | |
| SCHEMBL29689364 | 0.84 | MAPK7 (0.39) | MAPK7ADAMTS5HSD11B1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HTR1D 4084/4885HTR1B 3023/4885MAPK7 390/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HTR1D 4204/4885HTR1B 3158/4885MAPK7 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.